Anita Sveen

  • Project group leader, Associate professor
  • +47 2278 1719

ORCID: 0000-0001-8219-6251


Biosketch

Current positions

Project group leader in Computational Oncology & Deputy group leader of the Lothe lab

Associate Professor at Inst. Clinical Medicine, University of Oslo

Academic degrees

2012: PhD in Cancer Genomics, Faculty of Medicine, University of Oslo, Norway

2007: MSc in Molecular Biology, Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Norway


Research

Translational research of colorectal cancer: genomics and transcriptomics in precision cancer medicine

Tumor heterogeneity: computational modeling of subclonal evolution and phenotypic plasticity in multiregional and multi-lesion samples of primary and metastatic tumors

Pharmacogenomics of colorectal cancer: integration of pharmacological data from drug screens of preclinical models with molecular profiles to identify the mechanisms and predictive biomarkers of treatment response


Fellowships and awards

2021: Dr Ragnar Mørk’s legacy prize for excellent cancer research

2020: Researcher of the Year, Inst. Cancer Research and the Norwegian Radium Hospital Legacy

2019: Early Career Award, Oslo University Hospital

2018: Appointed Associate Professor, Inst. Clinical Medicine, University of Oslo

2017: Young Investigator Award, Onkologisk Forum

2015: Personal researcher grant, the Norwegian Cancer Society


Funding

2023-2027: Converting inoperable to curable metastatic cancer (translational research in transplant oncology). The Norwegian Cancer Society

2023-2026: Functional treatment decision tools in solid tumors. South-Eastern Norway Regional Health Authorities

2023-2026: Functional precision oncology of colorectal cancer. Division of Cancer Medicine, Oslo University Hospital

2020-2025: PRIMO CRC: precision immuno-oncology for colorectal cancer. The Norwegian Cancer Society

2019-2024: TEAM-ACT: tumor evolution in advanced models to accelerate precision cancer therapy. Oslo University Hospital Strategic Research Area

2019-2024: Catching up with metastatic colorectal cancer heterogeneity. Research Council of Norway

2019-2023: CLEVER: clonal evolution and evaluation of response to targeted treatment in BRAF mutant metastatic colorectal cancer. South-Eastern Norway Regional Health Authorities


Selected publications (as first or senior author)

Langerud J, Eilertsen IA, Moosavi SH, Klokkerud SM, Backe I, Hektoen M, Sjo O, Jeanmougin M, Tejpar S, Nesbakken A, Lothe RA, Sveen A. Multiregional transcriptomics identifies congruent consensus molecular subtypes with prognostic value beyond tumor heterogeneity in colorectal cancer. Under review at Nature Portfolio. DOI 10.21203/rs.3.rs-3290125/v1

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA. Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight 2024 (in press). DOI 10.1172/jci.insight.170423

Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Med 2021;13:143

Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMed 2020;59:102923

Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA. Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clin Cancer Res 2018;24(4):794-806


Computational tool

CMScaller: R package for consensus molecular subtyping of colorectal cancer preclinical models (v.1.0) and liver metastases (v.2.0)


Innovation

Granted patent (US and Europe) and 4 patent applications for biomarkers of colorectal cancer.


Invited presentations (recent international meetings)

2023: Nordic Precision Cancer Medicine Symposium, Oslo, Norway. “Functional oncology of metastatic colorectal cancer in the context of tumor heterogeneity

2023: European Association for Cancer Research and Organisation for European Cancer Institutes (EACR-OECI) Molecular Pathology Approach to Cancer, Bergamo, Italy. “Multiregional molecular profiling of colorectal cancers defines prognostic features less vulnerable to tumor heterogeneity

2022: American Association for Cancer Research (AACR) Special Conference: Colorectal Cancer, Portland, Oregon, USA. “Tumor organoids of multi-metastatic colorectal cancer: From research tools to treatment decision tools


Outreach (selected articles)

2021: Popular science article in Aftenposten about personal treatment modelling using tumor organoids

2020: Interview at NRK Distriktsnyheter Innlandet

2015-2020 Popular science articles at the official websites of The Norwegian Cancer Society and NORILCO, and interviews at forskning.no and the TEKNA magazine


Complete publication list

 

Publications 2024

Langerud J, Eilertsen IA, Moosavi SH, Klokkerud SMK, Reims HM, Backe IF, Hektoen M, Sjo OH, Jeanmougin M, Tejpar S, Nesbakken A, Lothe RA, Sveen A (2024)
Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer
Nat Commun, 15 (1), 4342
DOI 10.1038/s41467-024-48706-2, PubMed 38773143

Majid U, Bergsland CH, Sveen A, Bruun J, Eilertsen IA, Bækkevold ES, Nesbakken A, Yaqub S, Jahnsen FL, Lothe RA (2024)
The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration
Cell Oncol (Dordr), 47 (4), 1267-1276
DOI 10.1007/s13402-024-00926-w, PubMed 38407700

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Publications 2023

Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
EBioMedicine, 97, 104829
DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Publications 2022

Bergsland CH, Jeanmougin M, Moosavi SH, Svindland A, Bruun J, Nesbakken A, Sveen A, Lothe RA (2022)
Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer
Mod Pathol, 35 (9), 1236-1246
DOI 10.1038/s41379-022-01086-8, PubMed 35484226

Kryeziu K, Bergsland CH, Guren TK, Sveen A, Lothe RA (2022)
Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars
Biochim Biophys Acta Rev Cancer, 1877 (1), 188682
DOI 10.1016/j.bbcan.2022.188682, PubMed 35065193

Strømme JM, Johannessen B, Kidd SG, Bogaard M, Carm KT, Zhang X, Sveen A, Mathelier A, Lothe RA, Axcrona U, Axcrona K, Skotheim RI (2022)
Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity
Cancer Gene Ther, 29 (8-9), 1276-1284
DOI 10.1038/s41417-022-00444-7, PubMed 35194199

Publications 2021

Berg KCG, Brunsell TH, Sveen A, Alagaratnam S, Bjørnslett M, Hektoen M, Brudvik KW, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA (2021)
Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases
Mol Oncol, 15 (4), 830-845
DOI 10.1002/1878-0261.12885, PubMed 33325154

Eide PW, Moosavi SH, Eilertsen IA, Brunsell TH, Langerud J, Berg KCG, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA, Sveen A (2021)
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
NPJ Genom Med, 6 (1), 59
DOI 10.1038/s41525-021-00223-7, PubMed 34262039

Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA (2021)
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
J Transl Med, 19 (1), 384
DOI 10.1186/s12967-021-03062-3, PubMed 34496878

Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A (2021)
De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
Genome Med, 13 (1), 143
DOI 10.1186/s13073-021-00956-1, PubMed 34470666

Slørdahl KS, Klotz D, Olsen JÅ, Skovlund E, Undseth C, Abildgaard HL, Brændengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
Acta Oncol, 60 (7), 921-930
DOI 10.1080/0284186X.2021.1918763, PubMed 33966592

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
The expressed mutational landscape of microsatellite stable colorectal cancers
Genome Med, 13 (1), 142
DOI 10.1186/s13073-021-00955-2, PubMed 34470667

Publications 2020

Bergsland CH, Bruun J, Guren MG, Svindland A, Bjørnslett M, Smeby J, Hektoen M, Kolberg M, Domingo E, Pellinen T, Tomlinson I, Kerr D, Church DN, Nesbakken A, Sveen A, Lothe RA (2020)
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
ESMO Open, 5 (6), e001040
DOI 10.1136/esmoopen-2020-001040, PubMed 33219056

Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA (2020)
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Clin Cancer Res, 26 (15), 4107-4119
DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813

Flatin BTB, Vedeld HM, Pinto R, Langerud J, Lind GE, Lothe RA, Sveen A, Jeanmougin M (2020)
Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability
Int J Cancer, 148 (7), 1652-1657
DOI 10.1002/ijc.33425, PubMed 33284993

Jeanmougin M, Håvik AB, Cekaite L, Brandal P, Sveen A, Meling TR, Ågesen TH, Scheie D, Heim S, Lothe RA, Lind GE (2020)
Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment
Mol Oncol, 14 (5), 1016-1027
DOI 10.1002/1878-0261.12668, PubMed 32171051

Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020)
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
EBioMedicine, 59, 102923
DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

Berg KCG, Sveen A, Høland M, Alagaratnam S, Berg M, Danielsen SA, Nesbakken A, Søreide K, Lothe RA (2019)
Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
Oncogene, 38 (33), 6109-6122
DOI 10.1038/s41388-019-0868-5, PubMed 31308487

Brunsell TH, Cengija V, Sveen A, Bjørnbeth BA, Røsok BI, Brudvik KW, Guren MG, Lothe RA, Abildgaard A, Nesbakken A (2019)
Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases
Eur J Surg Oncol, 45 (12), 2340-2346
DOI 10.1016/j.ejso.2019.07.017, PubMed 31350075

Brunsell TH, Sveen A, Bjørnbeth BA, Røsok BI, Danielsen SA, Brudvik KW, Berg KCG, Johannessen B, Cengija V, Abildgaard A, Guren MG, Nesbakken A, Lothe RA (2019)
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
Clin Colorectal Cancer, 19 (1), e26-e47
DOI 10.1016/j.clcc.2019.09.003, PubMed 31982351

Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J (2019)
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
Ann Oncol, 30 (10), 1622-1629
DOI 10.1093/annonc/mdz287, PubMed 31504112

Eide PW, Eilertsen IA, Sveen A, Lothe RA (2019)
Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties
Int J Cancer, 144 (11), 2843-2853
DOI 10.1002/ijc.31998, PubMed 30447009

Eilertsen IA, Moosavi SH, Strømme JM, Nesbakken A, Johannessen B, Lothe RA, Sveen A (2019)
Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer
Cancer Lett, 469, 246-255
DOI 10.1016/j.canlet.2019.10.040, PubMed 31678167

Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN (2019)
Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
Br J Cancer, 121 (6), 474-482
DOI 10.1038/s41416-019-0540-4, PubMed 31388185

Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN (2019)
Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
Br J Cancer, 121 (9), 807
DOI 10.1038/s41416-019-0590-7, PubMed 31548598

Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA (2019)
Combination therapies with HSP90 inhibitors against colorectal cancer
Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
DOI 10.1016/j.bbcan.2019.01.002, PubMed 30708039

Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, Hektoen M, Guren MG, Nesbakken A, Bruun J, Lothe RA (2019)
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
ESMO Open, 4 (3), e000523
DOI 10.1136/esmoopen-2019-000523, PubMed 31321083

Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, Johannessen B, Hektoen M, Skotheim RI, Guren MG, Nesbakken A, Lothe RA (2019)
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
Oncogenesis, 8 (6), 35
DOI 10.1038/s41389-019-0141-3, PubMed 31092812

Sveen A, Cremolini C, Dienstmann R (2019)
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes
Ann Oncol, 30 (11), 1682-1685
DOI 10.1093/annonc/mdz412, PubMed 31868904

Sveen A, Kopetz S, Lothe RA (2019)
Biomarker-guided therapy for colorectal cancer: strength in complexity
Nat Rev Clin Oncol, 17 (1), 11-32
DOI 10.1038/s41571-019-0241-1, PubMed 31289352

Publications 2018

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA (2018)
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
Mol Oncol, 12 (9), 1639-1655
DOI 10.1002/1878-0261.12347, PubMed 29900672

Eilertsen IA, Sveen A, Strømme JM, Skotheim RI, Nesbakken A, Lothe RA (2018)
Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
Int J Cancer, 144 (4), 841-847
DOI 10.1002/ijc.31809, PubMed 30121958

Høland M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, Mandahl N, van den Berg E, Smeland S, Mertens F, Sundby Hall K, Picci P, Sveen A, Lothe RA (2018)
Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53
Mod Pathol, 31 (11), 1694-1707
DOI 10.1038/s41379-018-0074-y, PubMed 29946184

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA (2018)
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Ann Oncol, 29 (5), 1227-1234
DOI 10.1093/annonc/mdy085, PubMed 29518181

Publications 2017

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Mol Cancer, 16 (1), 116
DOI 10.1186/s12943-017-0691-y, PubMed 28683746

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J (2017)
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
Ann Oncol, 28 (5), 1023-1031
DOI 10.1093/annonc/mdx052, PubMed 28453697

Eide PW, Bruun J, Lothe RA, Sveen A (2017)
CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
Sci Rep, 7 (1), 16618
DOI 10.1038/s41598-017-16747-x, PubMed 29192179

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA (2017)
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Clin Cancer Res, 24 (4), 794-806
DOI 10.1158/1078-0432.CCR-17-1234, PubMed 29242316

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
Genome Med, 9 (1), 46
DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Publications 2016

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J, Epicolon consortium, de Bruyn M, Nijman HW et al. (2016)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Lancet Gastroenterol Hepatol, 1 (3), 207-216
DOI 10.1016/S2468-1253(16)30014-0, PubMed 28404093

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS (2016)
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
DOI 10.1016/j.urolonc.2016.10.002, PubMed 27838142

Ramalho-Carvalho J, Martins JB, Cekaite L, Sveen A, Torres-Ferreira J, Graça I, Costa-Pinheiro P, Eilertsen IA, Antunes L, Oliveira J, Lothe RA, Henrique R, Jerónimo C (2016)
Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1
Cancer Lett, 385, 150-159
DOI 10.1016/j.canlet.2016.10.028, PubMed 27984115

Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA (2016)
Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
PLoS Genet, 12 (7), e1006225
DOI 10.1371/journal.pgen.1006225, PubMed 27472274

Publications 2015

Hoff AM, Johannessen B, Alagaratnam S, Zhao S, Nome T, Løvf M, Bakken AC, Hektoen M, Sveen A, Lothe RA, Skotheim RI (2015)
Novel RNA variants in colorectal cancers
Oncotarget, 6 (34), 36587-602
DOI 10.18632/oncotarget.5500, PubMed 26474385

Johannessen B, Sveen A, Skotheim RI (2015)
TIN: An R Package for Transcriptome Instability Analysis
Cancer Inform, 14, 109-12
DOI 10.4137/CIN.S31363, PubMed 26448683

Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI (2015)
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Oncogene, 35 (19), 2413-27
DOI 10.1038/onc.2015.318, PubMed 26300000

Publications 2014

Oppelt A, Haugsten EM, Zech T, Danielsen HE, Sveen A, Lobert VH, Skotheim RI, Wesche J (2014)
PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1
Biochem J, 461 (3), 383-90
DOI 10.1042/BJ20140132, PubMed 24840251

Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323

Sveen A, Johannessen B, Teixeira MR, Lothe RA, Skotheim RI (2014)
Transcriptome instability as a molecular pan-cancer characteristic of carcinomas
BMC Genomics, 15 (1), 672
DOI 10.1186/1471-2164-15-672, PubMed 25109687

Publications 2013

Alagaratnam S, Harrison N, Bakken AC, Hoff AM, Jones M, Sveen A, Moore HD, Andrews PW, Lothe RA, Skotheim RI (2013)
Transforming pluripotency: an exon-level study of malignancy-specific transcripts in human embryonal carcinoma and embryonic stem cells
Stem Cells Dev, 22 (7), 1136-46
DOI 10.1089/scd.2012.0369, PubMed 23137282

Sveen A, Nesbakken A, Ågesen TH, Guren MG, Tveit KM, Skotheim RI, Lothe RA (2013)
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
DOI 10.1158/1078-0432.CCR-13-1769, PubMed 24166914

Publications 2012

Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA (2012)
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
Gut, 61 (11), 1560-7
DOI 10.1136/gutjnl-2011-301179, PubMed 22213796

Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, Teixeira MR (2012)
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements
Neoplasia, 14 (7), 600-11
DOI 10.1593/neo.12600, PubMed 22904677

Sveen A, Bakken AC, Ågesen TH, Lind GE, Nesbakken A, Nordgård O, Brackmann S, Rognum TO, Lothe RA, Skotheim RI (2012)
The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer
Int J Cancer, 131 (6), 1479-85
DOI 10.1002/ijc.27399, PubMed 22173985

Sveen A, Ågesen TH, Nesbakken A, Meling GI, Rognum TO, Liestøl K, Skotheim RI, Lothe RA (2012)
ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients
Clin Cancer Res, 18 (21), 6001-10
DOI 10.1158/1078-0432.CCR-11-3302, PubMed 22991413

Publications 2011

Danielsen SA, Cekaite L, Ågesen TH, Sveen A, Nesbakken A, Thiis-Evensen E, Skotheim RI, Lind GE, Lothe RA (2011)
Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome
PLoS One, 6 (9), e24419
DOI 10.1371/journal.pone.0024419, PubMed 21909432

Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA, Skotheim RI (2011)
Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival
Genome Med, 3 (5), 32
DOI 10.1186/gm248, PubMed 21619627

Publications 2009

Mathiesen G, Sveen A, Brurberg MB, Fredriksen L, Axelsson L, Eijsink VG (2009)
Genome-wide analysis of signal peptide functionality in Lactobacillus plantarum WCFS1
BMC Genomics, 10, 425
DOI 10.1186/1471-2164-10-425, PubMed 19744343

Publications 2008

Mathiesen G, Sveen A, Piard JC, Axelsson L, Eijsink VG (2008)
Heterologous protein secretion by Lactobacillus plantarum using homologous signal peptides
J Appl Microbiol, 105 (1), 215-26
DOI 10.1111/j.1365-2672.2008.03734.x, PubMed 18298538

Page visits: 15003